While mammograms are the current gold standard for breast cancer detection, having dense breast tissue increases false-finding risks

A new study demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

“Women who have dense breasts are at a double disadvantage. Not only are they at higher risk of developing breast cancer, but dense breast tissue can decrease the reliability of imaging and increase the chances of a false finding.” said Judith K. Wolf, MD, Chief Medical Officer of Provista Diagnostics, Inc.

“This study shows that, with an over 99 percent negative predictive value (NPV), clinicians can confidently use Videssa Breast to detect cancer in women with dense breasts and better determine when biopsy is truly warranted to assess suspicious findings.”

The study evaluated the performance of Videssa Breast among 545 women, ages 25 to 50, with abnormal or difficult-to-interpret imaging (BI-RADS 3 and 4).

WIN a R 2,000 Woolworths Voucher

Subscribe to our Free Daily All4Women Newsletter to enter

Related: Breast cancer screening: What you need to know about mammograms and ultrasounds

Are you dense?

The challenge of diagnosing breast cancer in women with dense breasts has drawn attention in recent years.

Driven by patient advocacy groups such as Are You Dense? Inc. and Are You Dense Advocacy, Inc., 32 US states have enacted legislation to ensure women are informed of their breast density status and the associated diagnostic challenges.

Related: Changes in breast density related to breast cancer

Videssa Breast is currently available for use in the US by ordering healthcare providers for patients with abnormal imaging findings.

Source: Provista Diagnostics via www.sciencedaily.com

While All4Women endeavours to ensure health articles are based on scientific research, health articles should not be considered as a replacement for professional medical advice. Should you have concerns related to this content, it is advised that you discuss them with your personal healthcare provider.